DDR1 and Alzheimer disease: To address the question of DDR1 effects on blood vessels and inflammation in dementia, we performed longitudinal epigenomic studies via unbiased next generation whole miRNA genome sequencing of CSF obtained from mild–moderate AD patients who were treated with nilotinib (versus placebo), which significantly reduced CSF Aβ levels and CNS amyloid burden as measured with Positron Emission Tomography (PET) [33].